Neuland Laboratories Ltd. · NSE:NEULANDLAB
Neuland Laboratories — Q1 FY27 Earnings Presentation
37 slides from Neuland Laboratories's earnings presentation, Aug 5, 2026
Slide 1: Exchange filing cover letter for Investors/Analysts Presentation
August 5, 2026 To BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, 25th Floor, Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Investors/Analysts
Slide 2: Neuland Laboratories Limited Investor Presentation Q1FY27
Neuland Laboratories Limited Investor Presentation Q1FY27
Slide 3: Safe Harbour
SAFE HARBOUR Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 4: Table of Content
Table of Content Q1FY27 Highlights Company Overview Business Strategy Our Businesses Shareholder Information Q1FY27 Company Business Our Shareholder Annexure Annexure Highlights Overview Strategy Businesses Information 3
Slide 5: Q1FY27 Highlights
Q1FY27 Highlights 4
Slide 6: Management Commentary
Management Commentary SAHARSH DAVULURI, CEO & MD “Q1 FY27 was broadly in line with our expectations with encouraging performance from both CMS & GDS businesses and represents a good start to the year. While Commercial Products contributed to most of the revenue, we are seeing exciting developments i
Slide 7: Q1FY27 Business Overview
Q1FY27 Business Overview CMS CMS revenues driven by commercial molecules. Growth in new projects orders which will be delivered over the course of this and next financial years. Traction from Innovators with peptides molecules in pipeline. GDS In Prime segment Ezetimibe and Mirtazapine were the key
Slide 8: Q1FY27 Financial Highlights
Q1FY27 Financial Highlights Total Income EBITDA PAT EPS (Rs. Cr) (Rs. Cr) (Rs. Cr) (Rs.) 40.5% 26.9% 22.7% 350.0 30.4% 35.5% 300.0 18.7% 212.5 250.0 19.0% 200.0 165.6 319.4 114.9 14.0% 9.0% 788.7 4.6% 231.1 150.0 147.4 650.1 516.1 156.9 447.8 75.2 100.0 96.5 300.6 42.1 10.7 85.0 31.5 13.7 40.4 50.0
Slide 9: Key Balance Sheet Metrics
Key Balance Sheet Metrics Current Ratio(x) ROCE % Fixed Asset Turnover (x) Debt to Equity (x) 35.8% 3.2 3.1 0.1 2.4 32.8% 2.7 0.1 0.1 2.6 2.2 2.1 0.1 2.1 26.1% 2.3 1.7 21.3% 0.1 17.9% FY23 FY24 FY25 FY26 Q1FY27 FY23 FY24 FY25 FY26 Q1FY27 FY23 FY24 FY25 FY26 Q1FY27 FY23 FY24 FY25 FY26 Q1FY27 Particul
Slide 10: Key Operating Metrics Q1FY27
Key Operating Metrics Q1FY27 Top 10 & Top 5 Products Top 10 & Top 5 Customers Segment revenue Prime Specialty Top 10 Top 10 CMS Others Top 5 Top 5 4% 6% 6% 100% 99% 7% 6% 99% 89% 96% 80% 96% 77% 44% 79% 65% 60% 61% 72% 68% 67% 70% 63% 54% 16% 11% 41% 40% 11% 8% 8% 32% 26% 22% 18% 18% Q1FY26 Q2FY26 Q
Slide 11: CMS – Revenue Split & Number of Active Projects
CMS – Revenue Split & Number of Active Projects Rs. Cr YoY Movement No. of active CMS projects Q1 FY27 Pre-Clinical P-1 P-2 P-3 Pre-Reg/Reg Commercial Grand Total API 15 13 13 5 4 9 59 Intermediate 2 10 7 8 3 10 40 418 Grand Total 17 23 20 13 7 19 99 120 14 20 Q1 FY26 Pre-Clinical P-1 P-2 P-3 Pre-Re
Slide 12: Company Overview
Company Overview 11
Slide 13: Company Overview
Company Overview Manufacturing of generic Generic APIs non-exclusive APIs Established in Business 1984 verticals Contract development and 40 years in API manufacturing CDMO Services manufacturing of NCE API and development Total reactor volume of 12,26,000 Liters Facilities Inspected by Supported 3
Slide 14: Key Facts
Key Facts 40+ 1010+ 100+ 92% Years of experience DMFs Filed API across 10 diverse Revenue from exports worldwide therapeutic areas 80+ 75 1226 KL 2272 Countries Served Active US DMFs API Manufacturing Employees Capacity 13
Slide 15: Board Of Directors
Board Of Directors Dr. Davuluri D. Sucheth Rao D. Saharsh Rao Mr. Prasad Mr. Homi Rustam Rama Mohan Rao Executive Vice Chief Executive Officer Raghavan Menon Khusrokhan Executive Chairman Chairman & Managing Director Independent Independent Director Director Dr. Ravi Shankar Ms. Pallavi Joshi Mr. Su
Slide 16: Key Milestones
Key Milestones Our Journey 2018 2019 2020 2021 2023 2024 2025 Acquisition of Increased flow of $100 M+ revenue over Unit – III Crossed INR 10 US FDA audit US FDA audit of advanced projects from CMS 75 live CMS projects Commercialization bn revenue. of Unit-I Unit-II intermediates & Japan. US FDA aud
Slide 17: Our Global Presence
Our Global Presence* EUROPE 50% APAC NORTH AMERICA 2% 42% BD office in Princeton, New Jersey Since 2004 JAPAN 1% BD office in Tokyo, Japan Since 2007 LATAM INDIA 2% 1% Headquarters in MENA Hyderabad, India 3 Manufacturing 2% Units Manufacturing and Development partner to customers in over 80 Countri
Slide 18: Manufacturing Facilities Overview
Manufacturing Facilities Overview UNIT - I UNIT - II UNIT - III Bonthapally, Hyderabad 256 kL Pashamylaram, Hyderabad 389 kL Gaddapotharam, Hyderabad 581 kL Year of 1986 1994 2017 Establishment Blocks Block - 1, 2, 3, 4, H, kL & S Block-1, 2, 3, FC, NMSM, Mini plant(A&B) Block - 1, 2, 4, 5, 6, 7 & 8
Slide 19: State-of-the-art R&D Centre
State-of-the-art R&D Centre Infrastructure Significant R&D achievements • 15 Development Labs with space • Several NCE APIs added in NDA or for expansion commercial stage drugs • 70 Fume hoods • Support for multiple APIs each year in • Analytical Labs Phase 2 and Phase 3 clinical candidates • Dedica
Slide 20: Regulatory Filings
Regulatory Filings 75 33 10 17 26 DMFs with Filings with Japanese China DMF Filings with USFDA Health Canada DMF filed filed KFDA Korea 28 291 ~499 31 1010+ Filings with ROW filings EUDMF filings CEPs received Filings till date TGA including across Germany, for different Turkey, Mexico, France, Pola
Slide 21: Financial Highlights FY2017-2026
Financial Highlights FY2017-2026 Rs. Crore Particulars FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026 Total Income 588.9 533.7 670.3 766.6 953.0 953.2 1,200.9 1,571.1 1,497.3 2,053.1 EBITDA 106.9 54.6 61.4 105.3 162.5 144.3 281.1 474.5 342.8 603.4 EBITDA Margin 18.1% 10.2% 9.2
Slide 22: Business Strategy
Business Strategy 21
Slide 23: Neuland Strategy Framework
Neuland Strategy Framework 04 Digitize to enable transparency, compliance, speed of decision making and ease of doing business 01 Invest in new technologies that are valued by our customers and help us differentiate vs. peers 05 Build a world-class talent pipeline and employee value proposition to e
Slide 24: Our Businesses
Our Businesses 23
Slide 25: Generic APIs (GDS)
Generic APIs (GDS) • We are a preferred service provider in the • API manufacturing heritage of over 40 years manufacturing of Active Pharmaceutical Ingredients (APIs) • Flexible 100g to hundreds of tons capacity • Have developed processes for over 100 • Non-competitive advantage (does not APIs with
Slide 26: CDMO Services (CMS)
CDMO Services (CMS) cGMP manufacturing of RSMs/KSMs/Intermediates and APIs for clinical trials and commercial supply Chemistry & manufacturing capabilities Synthetic portion of Carbohydrate Process fermented molecules chemistry optimization IND/NDA filing Deuterated Cyclic and support molecules PEGy
Slide 27: Shareholder Information
Shareholder Information 26
Slide 28: Shareholding Details
Shareholding Details Share Information (as on 30th June 2026) NSE Ticker NEULANDLAB BSE Ticker 524558 Others 30% Market Cap (Rs. Cr) 23,902.34 Promoters 33% % free-float 67.38% Free-float market cap (Rs. Cr) 16,105 FII Shares Outstanding 1,28,29,889 21% DII 3M Average Daily Traded Volume (ADTV) 60,0
Slide 29: Annexure
Annexure 28
Slide 30: Profit & Loss Snapshot (Standalone)
Profit & Loss Snapshot (Standalone) Rs. Crore Particulars Q1FY27 Q1FY26 YoY (%) Q4FY26 QoQ (%) Total Income 650.1 300.6 116.3% 788.7 -17.6% EBITDA 231.1 42.1 448.2% 319.4 -27.6% EBITDA Margin 35.5% 14.0% 2150 bps 40.5% -500 bps Profit Before Tax 197.5 17.4 1036.7% 287.0 -31.2% PBT Margin 30.4% 5.8%
Slide 31: Revenue & PBT trend
Revenue & PBT trend Rs Cr Revenue 789 650 516 415 421 444 448 365 395 390 402 315 336 301 294 270 222 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 PBT* 287 198 121 130 128 129 110 104 84 92 53 49 54 39 39 13 17 Q1FY23 Q2FY23 Q
Slide 32: Vision and Values
We are creating a healthier world through sustainable practices, trusted partnerships, and agile collaboration Vision and Values (— Innovation Innovative in everything we do (% Transparency Transparent and open in our communication (a Accountability Accountable for our delivery g Empathy Empathy in
Slide 33: Sustainability Framework: ESG commitment & Goals (1/3)
Sustainability Framework: ESG commitment & Goals (1/3) Environment Focus area Our commitments Key ESG goals (included in Balance Scorecard) • FY 2033-34: 58.8%* reduction in Scope 1 & 2 emissions (FY 2023-24 baseline) • Reduce both direct (Scope 1 & 2) and indirect • FY 2049-50: Achieve Net Zero in
Slide 34: Sustainability Framework: ESG commitment & Goals (2/3)
Sustainability Framework: ESG commitment & Goals (2/3) Social Focus area Our commitments Key ESG goals (included in Balance Scorecard) • Maintain Zero Fatality Occupational health • Strive for zero harm environment across all • Maintain Nil Long-term Injury and Safety operations • Frequency Rate (LT
Slide 35: Sustainability Framework: ESG commitment & Goals (3/3)
Sustainability Framework: ESG commitment & Goals (1/3) Governance Focus area Our commitments Key ESG goals (included in Balance Scorecard) Product Quality and Regulatory • Strong Quality Culture • Maintain 100% compliance across GMP operations compliance Business • Build resilience through enterpris
Slide 36: Glossary
Glossary Term Description Term Description Any substance that is intended for incorporation into a finished drug Drugs (small or large molecule) under development by a Pipeline drugs Active Pharmaceutical product and is intended to furnish pharmacological activity or other manufacturer Ingredient (A
Slide 37: Thank you
Thank you For further information contact IR Desk Neuland Labs Contact: +91 40 6761 1600 Email: ir@Neulandlabs.com Runjun Jain/ Minakshi Machutre EY IR Contact: +91 22 6192 2000 Email: Runjhun.Jain1@in.ey.com / Minakshi.Machutre@in.ey.com